About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 3

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up

NCT00345878•GlaxoSmithKline

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Infections, Papillomavirus

Interventions

Placebo

HPV-16/18 L1 VLP AS04 (Cervarix TM)

Locations

2

Malaysia

Locations (2)

GSK Investigational Site

Kerajaan Persekutuan Putrajaya, Malaysia

GSK Investigational Site

Kuala Lumpur, Malaysia

Key Dates

Start Date

September 25, 2006

Primary Completion Date

December 21, 2007

Completion Date

December 21, 2007

Last Updated

July 20, 2018

Related Studies

COMPLETEDPhase 3

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

NCT01627561

Infections, Papillomavirus

COMPLETEDPhase 3

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

NCT00196937

Infections, Papillomavirus

COMPLETEDPhase 3

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357

Infections, Papillomavirus

COMPLETEDPhase 3

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176

Infections, Papillomavirus

COMPLETEDPhase 3

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

NCT01277042

Infections, Papillomavirus

COMPLETEDPhase 3

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

NCT00426361

Infections, Papillomavirus

View all related studies

Sponsors

Lead Sponsor

GlaxoSmithKline

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 20, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions